Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin plus necitumumab versus gemcitabine–cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer

BACKGROUND: SQUIRE demonstrated addition of necitumumab to gemcitabine and cisplatin significantly improved survival in patients with stage IV sq-NSCLC. Here, we report additional outcomes for the subpopulation of patients with tumor epidermal growth factor receptor (EGFR) protein expression. PATIEN...

Descripción completa

Detalles Bibliográficos
Autores principales: Paz-Ares, L., Socinski, M. A., Shahidi, J., Hozak, R. R., Soldatenkova, V., Kurek, R., Varella-Garcia, M., Thatcher, N., Hirsch, F. R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4959928/
https://www.ncbi.nlm.nih.gov/pubmed/27207107
http://dx.doi.org/10.1093/annonc/mdw214

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4959928/
https://www.ncbi.nlm.nih.gov/pubmed/27207107
http://dx.doi.org/10.1093/annonc/mdw214

Ejemplares similares